You have 9 free searches left this month | to do more

rituximab

Rituximab is a drug used to treat Lymphoma, Chronic Lymphocytic Leukemia, Leukemia, and other conditions. Rituximab is being actively studied in 373 studies and prior, has been studied in 616.

Top SponsorsTop SitesTop Investigators
M.D. Anderson Cancer CenterM D Anderson Cancer CenterAjay Gopal
Hoffmann-La RocheMayo ClinicJulie M Vose, MD
National Cancer Institute (NCI)University of Texas MD Anderson Cancer CenterSteven P. Treon, MD, PhD
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
M
Ibrutinib With or Without Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia
Active, not recruiting
  • Prolymphocytic Leukemia
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
2022-02-08
Feb 8, 2022
N
Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma
Active, not recruiting
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +3 more
  • Bronx, New York
  • +3 more
2022-04-05
Apr 5, 2022
N
Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery
Active, not recruiting
  • Ann Arbor Stage III Small Lymphocytic Lymphoma
  • +7 more
  • Washington, District of Columbia
  • +1 more
2022-04-05
Apr 5, 2022
M
Acalabrutinib, Lenalidomide, and Rituximab for the Treatment of CD20 Positive Stage III-IV, Grade 1-3a Follicular Lymphoma
Recruiting
  • Ann Arbor Stage III Grade 1 Follicular Lymphoma
  • +6 more
  • Houston, Texas
    M D Anderson Cancer Center
2022-02-08
Feb 8, 2022
M
Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell Lymphoma
Active, not recruiting
  • CCND1 Positive
  • +6 more
  • Houston, Texas
    M D Anderson Cancer Center
2022-01-11
Jan 11, 2022
F
Rituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell Lymphoma in Uganda
Recruiting
  • Burkitt Lymphoma
  • +2 more
  • Rituximab and Hyaluronidase Human
  • +8 more
  • Kampala, Uganda
    UCI-Fred Hutch Cancer Centre
2022-03-09
Mar 9, 2022
N
Atezolizumab, Gemcitabine, Oxaliplatin, and Rituximab in Treating Patients With Relapsed or Refractory Transformed Diffuse Large B-Cell Lymphoma
Recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • +5 more
  • Duarte, California
  • +3 more
2022-04-05
Apr 5, 2022
U
Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma
Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • +8 more
  • Ixazomib Citrate
  • +2 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
2021-10-20
Oct 20, 2021
M
Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage II-IV Follicular Lymphoma or Marginal Zone Lymphoma
Active, not recruiting
  • Ann Arbor Stage II Follicular Lymphoma
  • +9 more
  • Houston, Texas
    M D Anderson Cancer Center
2022-02-03
Feb 3, 2022
A
Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
Recruiting
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +13 more
  • Polatuzumab Vedotin
  • +3 more
  • Scottsdale, Arizona
  • +9 more
2022-04-07
Apr 7, 2022
O
Venetoclax, Dasatinib, Prednisone, and Rituximab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Not yet recruiting
  • B Acute Lymphoblastic Leukemia
  • Recurrent B Acute Lymphoblastic Leukemia
  • Portland, Oregon
    OHSU Knight Cancer Institute
2021-12-27
Dec 27, 2021
M
Fludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • Refractory Diffuse Large B-Cell Lymphoma
  • Chimeric Antigen Receptor T-Cell Therapy
  • +3 more
  • Sacramento, California
    University of California Davis Comprehensive Cancer Center
2022-03-08
Mar 8, 2022
U
Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma - 2021
Terminated
  • Lymphoid Leukemia
  • +3 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
2021-07-20
Jul 20, 2021
N
Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma
Active, not recruiting
  • Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma
  • +11 more
  • Washington, District of Columbia
  • +6 more
2022-04-05
Apr 5, 2022
M
Lenalidomide in Combination With Rituximab in Treating Participants With Stage III/IV Indolent Non-Hodgkin Lymphoma - 2020
Completed
Has Results
  • Ann Arbor Stage III Grade 1 Follicular Lymphoma
  • +9 more
  • Houston, Texas
    M D Anderson Cancer Center
2021-09-28
Sep 28, 2021
M
ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma
Recruiting
  • Aggressive B-Cell Non-Hodgkin Lymphoma
  • +19 more
  • CD47 Antagonist ALX148
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
2021-11-22
Nov 22, 2021
N
Compare Efficacy and Safety of Repeated Courses of Rituximab to That of Maintenance Mycophenolate Mofetil Following Single Course of Rituximab Among Children With Steroid Dependent Nephrotic Syndrome
Active, not recruiting
  • Steroid-Dependent Nephrotic Syndrome
  • Rituximab
  • Mycophenolate Mofetil
  • Kolkata, West Bengal, India
    Nilratan Sircar Medical College and Hospital
2022-04-06
Apr 6, 2022
W
Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma
Active, not recruiting
Has Results
  • Mantle Cell Lymphoma
  • Saint Louis, Missouri
    Washington University School of Medicine
2022-02-02
Feb 2, 2022
M
Acalabrutinib and Rituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma
Not yet recruiting
  • Mantle Cell Lymphoma
  • Houston, Texas
    M D Anderson Cancer Center
2021-02-24
Feb 24, 2021
L
Exploring Durable Remission With Rituximab in Antineutrophil Cytoplasmic Antibody(ANCA)-Associated Vasculitis
Recruiting
  • ANCA Associated Vasculitis
  • Rituximab
  • +3 more
  • Leiden, Zuid-Holland, Netherlands
  • +1 more
2021-09-06
Sep 6, 2021
M
Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study
Recruiting
  • Diffuse Large B-Cell Lymphoma
  • Houston, Texas
    M D Anderson Cancer Center
2022-03-03
Mar 3, 2022
O
Methotrexate, Mannitol, Rituximab, and Carboplatin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma
Active, not recruiting
  • Central Nervous System Lymphoma
  • Cincinnati, Ohio
  • +3 more
2021-09-15
Sep 15, 2021
U
Bendamustine and Rituximab Induction Therapy and Maintenance Rituximab and Lenalidomide in Previously Untreated CLL/SLL
Active, not recruiting
  • Lymphoid Leukemia
  • +2 more
  • Madison, Wisconsin
    University of Wisconsin
2021-10-07
Oct 7, 2021
Y
Zanubrutinib in Combination With R-CHOP (ZaR-CHOP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma
Recruiting
  • Diffuse Large B-Cell Lymphoma
  • +2 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
2022-02-23
Feb 23, 2022
N
Rituximab for Anti-cytokine Autoantibody-Associated Diseases - 2021
Completed
  • Pulmonary Alveolar Proteinosis (PAP)
  • Severe Mucocutaneous Candidiasis
  • Rituximab
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
2022-04-07
Apr 7, 2022